... The Merck-sponsored publication is among the evidence in the Australian trial in which the lead plaintiff in a class action suit alleges, among other things, that the company used misleading and deceptive marketing strategies in promoting Vioxx.
Nine of 29 articles in the second issue of the journal referred positively to Vioxx, and an additional 12 articles referred positively to another Merck drug, Fosamax, a bone treatment, Mr. Donovan said. ... [Donovan is an expert witness for the plaintiff.]
Elsevier issued a press release today saying that it is working on new guidelines for custom publications that it produces for pharmaceutical companies, so that they will be clearly identified as not being peer-reviewed medical journals.
So Merck's on trial. Will Elsevier ever be, for making money off a drug that it must have known has been reported to have killed people? I say they'll probably both get off scot-free. Once again, the consumer will pay.
Merck Elsevier fraud big pharma medical journals EditorMom